Summit's ivonescimab cuts death risk 27% versus Keytruda in lung cancer trial

Product / TechRegulation Impact 4
โดย Seeking Alpha·CNUS·Read original
Summary · why it matters

Summit Therapeutics said Sunday that its ivonescimab significantly extended survival compared with Merck's Keytruda in a late-stage lung cancer trial run by its partner Akeso in China. Ivonescimab reduced the risk of death by 27% versus Keytruda, also known as pembrolizumab, in previously untreated patients with advanced non-small cell lung cancer whose tumors expressed PD-L1, with median overall survival of 30.8 months against 22.6 months, an 8.2-month difference Summit called statistically significant. The Phase 3 HARMONi-2 trial enrolled 398 patients with a median follow-up of 36 months, and the results are being presented at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer in Seoul. In the 168-patient subgroup with high PD-L1 expression, ivonescimab cut the risk of death by 42%, while the benefit was smaller and not statistically reliable in patients with lower PD-L1 expression, where the hazard ratio was 0.85 with a confidence interval crossing 1.0. Serious treatment-related adverse events occurred in 29.9% of ivonescimab patients versus 21.6% for Keytruda, though discontinuations were slightly less frequent at 4.1% versus 5%, and Summit is now recruiting for the global Phase 3 HARMONi-7 trial, expected to enroll 780 patients, while the FDA reviews a separate application in previously treated EGFR-mutated lung cancer with a Nov. 14 decision deadline.

Impact on stocks 4

Biotech & Genomic Medicine± Mixed · 3 stocks
Akeso Inc
9926
▲ PositiveTechnologyrelevance

Akeso's partner trial of ivonescimab showed statistically significant survival benefit versus Keytruda in advanced NSCLC.

Merck & Company Inc
MRK
▼ NegativeCompetitionrelevance

Ivonescimab beat Merck's Keytruda with a 27% reduction in death risk and 8.2-month overall survival advantage in the HARMONi-2 trial.

Critical Materials & Supply Chain▲ · 1 stocks

Theme Impact 2

Related news

▲2

Akeso Wins China Phase I Clearance for AK158D1 Bispecific ADC

Akeso has secured Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. The clearance puts fresh attention on the company's pipeline as it pushes deeper into IO2.0 and ADC2.0. Akeso's shares recently traded at HK$90.5, up 3.37% over 90 days but down 20.12% year to date, against a consensus analyst price target of HK$158.28, with the most bullish target at HK$226.04 and the most bearish at HK$125.08. The company remains exposed to execution setbacks given its reliance on a handful of key drugs and a current net loss of CN¥967.2 million.
9926.HK ▲
Biotech & Genomic Medicine ▲
Simply Wall St·4hRead more →
▲2

Merck's KEYTRUDA Plus Padcev Wins CHMP Backing for EU Bladder Cancer

Merck received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The addressable group in Europe is relatively concentrated but clinically high need, with bladder cancer cases estimated at about 224,700 in 2022, roughly 25% of them classified as muscle invasive. The key near-term marker is the European Commission ruling expected by the fourth quarter of 2026, since the CHMP only issues recommendations.
MRKMRK.XETRA
Biotech & Genomic Medicine ▲
Simply Wall St·6hRead more →
impact 4

FDA Grants Full Approval to Lilly's Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer

Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo, or imlunestrant, in combination with Verzenio, or abemaciclib, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The decision rests on the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival versus Inluriyo alone, at 11.1 months versus 5.5 months, with a hazard ratio of 0.53 and a 95% confidence interval of 0.35 to 0.80, among the 159 patients with ESR1-mutated metastatic breast cancer. In that trial, 92 patients received Inluriyo alone and 67 received the combination after an aromatase inhibitor, with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic setting. The approval marks the second FDA clearance for Inluriyo in less than a year, following its September 2025 monotherapy approval for the same ER-positive, HER2-negative, ESR1-mutated metastatic population. Inluriyo is also being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for ER-positive, HER2-negative early-stage breast cancer, the largest adjuvant oral SERD trial with more than 8,000 patients enrolled across 650-plus sites in more than 30 countries, with initial results anticipated in 2027. The combination is now available in the United States.
LLY ▲
Biotech & Genomic Medicine ▲
PR Newswire·11hRead more →
© 2026 MarketDXNews